24/7 Market News Snapshot 27 September, 2024 – Estrella Immunopharma, Inc. Common Stock (NASDAQ:ESLA)

September 27, 2024

DENVER, Colo., 27 September, 2024 (247marketnews.com) – (NASDAQ:ESLA) are discussed in this article.
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has emerged as a key player in the biopharmaceutical sector, recently witnessing a notable surge in its stock price, which opened at $0.94 and increased by 47.85% to a peak of $1.434. The company’s robust trading volume of 1.14 million shares indicates a high level of investor interest, and technical indicators suggest a strong bullish trend. This surge coincides with the company’s advancements in its clinical trials, marking a significant moment for Estrella in the biotech landscape.

In a major breakthrough, Estrella has announced the successful outcome of its STARLIGHT-1 Phase I/II clinical trial, with the first patient achieving a complete response (CR) just one month after beginning treatment with the innovative EB103 CD19-Redirected ARTEMIS® T-Cell therapy. This promising development positions Estrella on a path to enhance T-cell therapies targeting cancer and autoimmune diseases. The trial reported no serious adverse events related to the treatment in a patient previously diagnosed with high-risk follicular lymphoma and who had undergone multiple relapses.

Cheng Liu, Ph.D., the President and CEO of Estrella, expressed cautious optimism, emphasizing the goal of developing ARTEMIS® T-cell therapies that not only improve upon the efficacy of existing CAR-T therapies but also address critical safety concerns. He highlighted the company’s commitment to making life-changing treatments accessible, including in community hospitals.

Furthermore, Principal Investigator Naseem Esteghamat, M.D., conveyed enthusiasm for the early safety and efficacy results, which encourage the continuation of the study. The STARLIGHT-1 trial comprises a multi-center, open-label design aimed at evaluating adults with relapsed or refractory B-cell non-Hodgkin lymphoma. With its promising early outcomes, Estrella Immunopharma is well-positioned to lead innovative advancements in oncology patient care.

Related news for (ESLA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.